WallStreetZenWallStreetZen

NYSE: EBS
Emergent Biosolutions Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for EBS

Based on 1 analyst offering 12 month price targets for Emergent Biosolutions Inc.
Min Forecast
$22.00+574.85%
Avg Forecast
$22.00+574.85%
Max Forecast
$22.00+574.85%

Should I buy or sell EBS stock?

Based on 1 analyst offering ratings for Emergent Biosolutions Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their EBS stock forecasts and price targets.

EBS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Benchmark
Bottom 12%
12
Strong BuyReiterates$22.00+574.85%2023-05-31

1 of 1

Forecast return on equity

Is EBS forecast to generate an efficient return?
Company
10.35%
Industry
162.35%
Market
48.98%
EBS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EBS forecast to generate an efficient return on assets?
Company
4.54%
Industry
15.61%
EBS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EBS revenue growth forecast

How is EBS forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
13.22%
Industry
11.68%
Market
11.91%
EBS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EBS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EBS vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
EBS$3.26$22.00+574.85%Strong Buy
ZOM$0.17N/AN/A
RGC$14.62N/AN/A
ASRT$2.60$7.50+188.46%Strong Buy
OPTN$1.26$3.00+138.10%Strong Buy
View Top Pharmaceutical Stocks

Emergent Biosolutions Stock Forecast FAQ

Is Emergent Biosolutions Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSE: EBS) stock is to Strong Buy EBS stock.

Out of 1 analyst, 1 (100%) are recommending EBS as a Strong Buy, 0 (0%) are recommending EBS as a Buy, 0 (0%) are recommending EBS as a Hold, 0 (0%) are recommending EBS as a Sell, and 0 (0%) are recommending EBS as a Strong Sell.

If you're new to stock investing, here's how to buy Emergent Biosolutions stock.

What is EBS's forecast return on equity (ROE) for 2023-2024?

(NYSE: EBS) forecast ROE is 10.35%, which is considered weak.

What is EBS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year EBS price target, the average EBS price target is $22.00, with the highest EBS stock price forecast at $22.00 and the lowest EBS stock price forecast at $22.00.

The Wall Street analyst predicted that Emergent Biosolutions's share price could reach $22.00 by May 31, 2024. The average Emergent Biosolutions stock price prediction forecasts a potential upside of 574.85% from the current EBS share price of $3.26.

What is EBS's forecast return on assets (ROA) for 2023-2024?

(NYSE: EBS) forecast ROA is 4.54%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 15.61%.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.